<DOC>
	<DOCNO>NCT00604396</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety efficacy insulin detemir combine oral anti-diabetic drug ( OADs ) versus insulin NPH combine oral anti-diabetic drug ( OADs ) Type 2 mellitus well control current therapy blood glucose control .</brief_summary>
	<brief_title>Safety Efficacy Insulin Detemir Combination With OAD Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes least 12 month since diagnosis Insulin naive subject OAD treatment least 4 month alone combine two OADs Body mass index ( BMI ) 35.0 kg/m2 HbA1c 7.510.0 % Able willing use twice day injection entire trial period Current previous treatment thiazolidiones within last 6 month OAD treatment three OADs within last 6 month Acute insulin treatment longer 7 day row within last 6 month Secondary diabetes Known maturity onset diabetes young ( MODY ) Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>